# Enliven Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Enliven Therapeutics, Inc.). ## Overview Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for cancer. Its lead program, ELVN-001, is designed to inhibit BCR-ABL for chronic myeloid leukemia, while the company also maintains earlier-stage research efforts such as HER2-directed work and other pipeline opportunities. ## Products & services • ELVN-001 BCR-ABL kinase inhibitor for chronic myeloid leukemia • ELVN-002 HER2-focused small-molecule program • Early-stage small-molecule oncology discovery programs • Preclinical and clinical development of precision-medicine candidates • Potential licensing or strategic alternatives for pipeline assets - **Clinical-stage oncology programs** (0%) — Lead drug candidates being advanced through clinical development, primarily ELVN-001 and related oncology assets. - **Preclinical discovery pipeline** (0%) — Earlier-stage small-molecule programs and target discovery efforts built around validated cancer biology. - **Strategic partnering / licensing** (0%) — Potential monetization of pipeline assets through licensing, collaboration, or other strategic alternatives. - **Research and development services** (0%) — Internal R&D activities, including chemistry, biology, clinical planning, and regulatory strategy. - ELVN-001 BCR-ABL inhibitor for chronic myeloid leukemia - ELVN-002 HER2 program and related strategic alternatives - Small-molecule oncology discovery and preclinical programs - Clinical development and regulatory advancement of product candidates - Potential out-licensing or partnering of pipeline assets ## Customers Enliven does not currently sell approved products, so its near-term 'customers' are primarily clinical investigators, trial participants, regulators, and potential future licensing partners. If its programs succeed, the eventual buyers would be physicians, hospitals, and payers treating patients with chronic myeloid leukemia or other oncology indications. - **Clinical trial ecosystem** (primary) — Hospitals, investigators, CROs, and trial participants supporting development of ELVN-001 and other candidates. - **Regulatory authorities** (primary) — FDA and comparable agencies that determine whether product candidates can advance and ultimately be approved. - **Potential licensing partners** (secondary) — Pharmaceutical companies that may license or co-develop ELVN-001, ELVN-002, or other assets. - **Future oncology treatment market** (emerging) — Physicians, hospitals, and payers that would buy approved therapies for CML or other cancers. - Clinical trial sites and investigators running ELVN-001 studies - Patients with chronic myeloid leukemia enrolled in trials - Regulators evaluating safety, efficacy, and approval packages - Potential pharma partners or licensees for pipeline assets - Future oncology prescribers, hospitals, and payers if approved ## Geography Enliven is headquartered in Boulder, Colorado and operates as a U.S.-based development company. Its business is concentrated in the United States, but clinical development, manufacturing, and regulatory activities can extend to third-party CROs, CMOs, and potential foreign regulators as programs advance. - Headquartered in Boulder, Colorado - Primary operating base is the United States - Clinical and regulatory work may expand internationally - Relies on third-party CROs and CMOs rather than owned plants - No owned manufacturing facilities planned ## Strategy The company is focused on advancing ELVN-001 through clinical development with a precision-medicine approach built on validated oncology targets. It is also preserving optionality through earlier-stage programs and potential strategic alternatives for ELVN-002, while relying on external partners for manufacturing and development execution. - **Advance ELVN-001 to later-stage clinical development** (short-term) — The company is substantially dependent on this lead asset for future value creation. - **Preserve pipeline optionality beyond ELVN-001** (medium-term) — A second asset or broader pipeline reduces single-asset concentration risk. - **Use external partners to limit fixed infrastructure** (short-term) — Outsourcing manufacturing and development supports a lean cost structure. - Advance ELVN-001 through clinical trials and regulatory review - Use validated targets and differentiated chemistry to improve success odds - Maintain optionality for ELVN-002 through strategic alternatives - Rely on CROs and CMOs to keep the operating model capital-light - Build a pipeline of small-molecule oncology assets beyond the lead program ## Risks Enliven is an early-stage, single-lead-asset biotech with no approved products and no product revenue, so clinical and regulatory outcomes dominate its risk profile. Its business also depends on external vendors, capital markets access, and the ability to manage safety, efficacy, and product liability risks as programs progress. - **Single-asset dependence on ELVN-001** [high] — If the lead program fails or is delayed, the company loses its main value driver. - **Clinical trial and regulatory failure** [high] — Early data may not predict later-stage success or satisfy FDA/EMA requirements. - **Ongoing losses and financing risk** [high] — The company has no product sales and must fund R&D through external capital. - **Product liability and safety exposure** [medium] — Therapeutic candidates can trigger claims, investigations, recalls, or restrictions. - **Third-party CRO/CMO dependence** [medium] — Delays or failures by vendors can disrupt timelines and increase costs. - No approved products means no commercial revenue and high development uncertainty - Heavy dependence on ELVN-001 creates single-asset concentration risk - Clinical trial results may fail to translate into approval - Cash burn and financing needs can pressure operations and dilution - Product liability and safety issues could delay or derail development ## Accounting As a clinical-stage biotech, Enliven’s reported results are driven mainly by R&D expense accruals, stock-based compensation, and lease costs rather than revenue recognition. Investors should watch estimates for accrued research and development, because vendor invoices and milestone timing can shift expenses between periods and affect comparability. - **Accrued research and development expense** — Can materially shift R&D expense between quarters - **Stock-based compensation** — Affects operating loss and non-cash expense profile - **Lease accounting** — Creates right-of-use assets and lease liabilities - **Clinical and product liability insurance** — May influence expense and disclosure of contingent liabilities - Accrued R&D expense affects period-to-period operating loss - Stock-based compensation is important in a talent-intensive biotech - Lease accounting affects facility-related liabilities and expenses - No product revenue yet, so expense recognition dominates results - Vendor and CRO/CMO commitments can create accrual estimates --- *Last updated: 2026-04-28T20:05:01.731481+00:00*